Endo Pharmaceuticals has revealed it is evaluating a notice from Anesiva advising of the filing of a new drug application for its Zingo topical powder product for the treatment of pain.
Subscribe to our email newsletter
<p>The notice referred to the patents that cover the method of use and formulation of Endo's lidocaine-containing topical patch products, Lidoderm and Synera. <br /><br />If approved, Endo believes that Zingo will not be a generic to, nor will it compete with, Lidoderm because of Zingo's indication and formulation. Anesiva's notice stated that Zingo's proposed indication is for preventing or reducing pain associated with blood draws and intravenous placements. <br /><br />Unlike Lidoderm, Zingo is not a topical patch. However, Endo believes that, although Zingo would not be a substitutable generic to Synera and uses a different delivery mechanism, Zingo may compete with Synera because their indications may be similar. Endo will continue to evaluate these notices.<br /><br />A new drug application for Zingo was filed in late 2006 and accepted for filing in January 2007.</p>